The Abu Dhabi Investment Authority and Singapore’s GIC have bought a minority stake in PPD, valuing the CRO giant at more than $9 billion.
NCGS is expanding its business by relocating to a new corporate headquarters, bringing $10 million in investment and creating 80 new jobs.
Neoantigen-based cancer vaccines represent new, truly personalized therapeutic approaches to treating cancer.
Amid new approvals last year, drugmakers also suffered R&D setbacks, cut research staff, rejigged their operations and refocused their pipelines.
Takeda is nearing the final stages of a joint venture with PRA Health Sciences, the product of an expansion of their clinical development partnership in Japan…
How PAREXEL's New Ecosystem of Technology, Processes and Expertise is Transforming Drug Development
A bipartisan bill that plans to allow a tax credit for expenses of contracted research—often done by CROs—has been introduced in the House of Representatives.
WuXi AppTec is seeking an IPO on China’s common stock market, a move that confirmed buzz that the CRO giant would re-enlist its businesses in three pieces.
Parexel has acquired contract medical affairs services provider The Medical Affairs Company as it looks to bolster its outsourced healthcare specialist…
PPD is opening a 24-bed clinical research unit in Las Vegas in support of its early drug development services.
WuXi AppTec, one of the largest CROs in China, has just acquired a Shanghai-based preclinical counterpart, HD Biosciences, building further on its core…
Evotec is participating in the €8 million ($8.46 million) Series A of its current partner in developing metabolic disease therapy Eternygen.